Division of Lung Transplant/Lung Failure
Ex vivo lung perfusion (EVLP) has developed as a novel organ preservation method in lung transplantation. EVLP allows us to evaluate lung graft function and condition prior to transplantation, leading to a possibility to utilize marginal lung grafts and/or high risk donor lungs including donation after circulatory death (DCD), atelectasis lung, lung with slight edema and functional problem without other concerns, as well as the lung grafts met to normal criteria.
This project is designed to assess the discarded nonacceptable human lungs using a perfusion system with the objective of establishing an internal infrastructure that will allow a subsequent phase to use these clinically approved perfusion systems to assess donor lung function prior to lung transplant.
To utilize this research registry with the purpose of conducting retrospective clinical research projects on patients who are being evaluated for and being treated with cardiac transplantation for end-stage congestive heart failure. This work will include documentation or rates of survival, adverse events, and outcomes based on pre-operative predictors and immunosuppression modality.
The primary goal is to maintain and support the donor lung at normothermic conditons to minimize damage and ischemic reperfusion injuries.
Primary endpoint: a composite of patient survival at day 30 post transplantation, and absence of ISHLT Primary Graft Dysfunction Grade 3 in the first 72 (between 0-72 hours) hours post-transplantation.
1. Incidence of ISHLT PGD Grade 3 at 72 hours post transplant.